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Objective: To compare the mean hospital discharge times and perioperative outcomes for radiofrequency volu-
metric thermal ablation (RFVTA) of ﬁbroids and laparoscopic myomectomy (LM). Methods: The present
postmarket, randomized, prospective, single-center, longitudinal, comparative study, conducted in Tübingen,
Germany, evaluated the outcomes of RFVTA and the current standard of care (LM) for symptomatic uterine ﬁ-
broids inwomenwho desired uterine conservation. The surgeonswere blinded to the treatment until all ﬁbroids
had beenmapped by laparoscopic ultrasound. Results: The mean hospitalization times were 10.0 ± 5.5 (median
7.8 [range 4.2–25.5]) hours for the RFVTA group and 29.9 ± 14.2 (median 22.6 [range 16.1–68.1]) hours for
the LM group (P b 0.001, Wilcoxon test). Intraoperative blood loss was 16 ± 9 (median 20 [range: 0–30]) mL
for the RFVTA procedures and 51± 57 (median 35 [range 10–300])mL for the LMprocedures. The percentage of
ﬁbroids imagedby laparoscopic ultrasound thatwere treated/excisedwas 98.6% for RFVTAand 80.3% for LM. Two
complicationswere reported: vertigo (n=1; RFVTA) and port site hematoma (n=1; LM). Conclusion: Radiofre-
quency volumetric thermal ablation resulted in the treatment of more ﬁbroids, a signiﬁcantly shorter hospital
stay, and less intraoperative blood loss than laparoscopic myomectomy.
ClinicalTrials.gov: NCT01750008
© 2014 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd.
Open access under CC BY-NC-ND license.1. Introduction
Uterine ﬁbroids are the most common pelvic neoplasms in women;
they severely impact the quality of life and are the leading indication for
a hysterectomy [1,2]. Hysterectomy is the deﬁnitive treatment for myo-
mas; however, many patients seek alternative uterine-sparing therapy
and desire to conserve their fertility.
Myomectomy is a much-reported surgical option for women with
symptomatic ﬁbroids and, until recently, the abdominal approach has
been the approach of choice for most surgeons. Over time, patients
have requested less invasive procedures and minimally invasive, lapa-
roscopic options are becoming more popular among patients and their
gynecologists [3]. With an extremely skilled laparoscopic surgeon, the
advantages of laparoscopic myomectomy (LM) over abdominal myo-
mectomy can include reduced blood loss, less postoperative pain,and Gynecology, University of
+49 7071 29 86224; fax: +49
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and Obstetrics. Published by Elsevier Ishorter hospital stay, andmore rapid recovery [4]. However, the techni-
cal challenges of multilayer laparoscopic suturing require skill and ex-
perience. Case reports of uterine rupture occurring in the second or
third trimester of pregnancy following LM have inspired recommenda-
tions against the laparoscopic approach in patients with myomas of
more than 5 cm in diameter, multiple myomas, or deep intramural my-
omas [5,6].
Laparoscopic radiofrequency volumetric thermal ablation (RFVTA)
provides a safe and effective outpatient treatment option for women
with symptomatic uterine ﬁbroids (including those larger than 5 cm)
and for womenwho desire uterine conservation [7–9]. The present ran-
domized study compared the outcomes of RFVTA with those of LM, the
standard of care.2. Materials and methods
Theprimary objective of the present studywas to compare themean
time to discharge from the hospital following laparoscopic treatment of
ﬁbroids by myomectomy or RFVTA. The secondary objective was to
compare perioperative outcomes. A 5-year follow-up is planned toreland Ltd. Open access under CC BY-NC-ND license.
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recurrence or regrowth of myomas, and reintervention rates.
The studywas a postmarket, randomized, prospective, single-center,
longitudinal, comparative study to evaluate the outcomes of RFVTA
and the current standard of care (LM) for symptomatic uterine ﬁbroids
in women who desire uterine conservation. After approval of the study
by the Clinical Ethics Committee at Tübingen University Hospital,
potential participants were enrolled between November 1, 2012, and
June 30, 2013 from referral centers within Germany. Inclusion and
exclusion criteria deﬁned eligibility (Box 1). After being informed of
the purpose of the study, the required testing, procedures, and assess-
ments, the expected duration, and the potential risks and beneﬁts of
study participation, 50 enrollees gave written informed consent and
were treated at Tübingen University Hospital. All participants wereBox 1
Inclusion and exclusion criteria
Inclusion criteria. Women who:
1 Are≥18 years old and menstruating
2 Have symptomatic uterine fibroids
3 Have a uterine size≤16 gestational weeks as determined by
pelvic exam
4 Have fibroids that are less than 10 cm in any diameter
5 Desire uterine conservation
6 Have had a normal Papanicolaou test
7 Are willing and able to comply with all study tests, procedures,
and assessment tools
8 Are capable of providing informed consent
Exclusion criteria. Women who:
1 Have contraindications for laparoscopic surgery and/or
general anesthesia
2 Are expected to be high risk for, or are known to have,
significant intra-abdominal adhesions (defined as adhesions
that would require extensive dissection to mobilize and view
all surfaces of the uterus)
3 Patients requiring major elective concomitant procedures
(e.g. hernia repair, hysteroscopic resection, endometrial
ablation, uterine artery ligation) that could confound the
results of the study
4 Are pregnant or lactating
5 Have taken any depot GnRH agonist within 3 months prior to
the screening procedures
6 Have an implanted intrauterine or fallopian tube device for
contraception that cannot or will not be removed at least
10 days prior to treatment
7 Have chronic pelvic pain not due to uterine fibroids
8 Have known or suspected endometriosis or adenomyosis
9 Have active or history of pelvic inflammatory disease
10 Have a history of, or evidence of, gynecologic malignancy or
pre-malignancy within the past 5 years
11 Have had pelvic radiation
12 Have a non-uterine pelvic mass over 3 cm
13 Have a cervical myoma
14 Have 1 or more completely intracavitary submucous fibroids
(type 0) or only type 0/1 submucous fibroids that are better
treated via hysteroscopic methods
15 In the medical judgment of the investigator should not
participate in the study
16 Are not willing to be randomized to treatment
Abbreviation: GnRH, gonadotropin-releasing hormone.women who desired uterine preservation and who were willing to be
randomized 1:1 to RFVTA or LM (Fig. 1).
Prior to randomization, all patients underwent contact laparoscopic
ultrasound (LUS) mapping with an Aloka SSD-4000 ultrasound system
and a standard Aloka LUS transducer (UST-5526L-7.5; Hitachi Aloka
Medical, Wallingford, CT, USA) for imaging and classiﬁcation of the
ﬁbroids according to their location and size (Fig. 2). Laparoscopic
ultrasound is a standard step before ﬁbroid treatment by RFVTA but
not before LM. The incorporation of LUS before randomization meant
that the surgeons had equal access to valuable imaging information
regardless of the procedure performed, and were able to plan the treat-
ment accordingly.
Once a patient’s ﬁbroids were mapped, classiﬁed, and recorded
on the treatment case report form, an envelope was drawn that
contained the patient’s treatment assignment. An independent
third-party statistician (Innovative Analytics, Kalamazoo, MI, USA)
performed a computer generation of the randomization assignments
in blocks of 6 or 4; the patient and the surgeon were blinded to the
treatment assignment.
Patients who were randomized to LM underwent the standard
surgical procedure in the lithotomy position with 2 additional 5-
mm ports and a uterine manipulator placed according to the rou-
tine practice of the surgeon investigators [10]. Vicryl 0 interrupted
sutures were used in a single layer. Two-layer suturing was
employed only for deep intramurals or intramurals without serosal
or endometrial distortion. Approximately 20 mL of epinephrine
(dilution 1:200) was instilled for vasoconstriction. If the 15-mm
morcellator was placed suprapubically and not at the ultrasound
port site, this counted as an additional incision. Myomectomy was
not performed on intramural myomas that were 1.0–1.5 cm in
diameter.
Patients whowere randomized to RFVTA remained in the dorsal po-
sition, had a tenaculum placed on the cervix, and were treated with the
Acessa system (HaltMedical, Brentwood, CA, USA), which consists of an
electrosurgical radiofrequency generator and a percutaneously inserted,
disposable radiofrequency handpiece with a deployable electrode array
(described in detail in the literature [7–9]). Two 10-mm ports were
placed: 1 for the laparoscope and 1 for the LUS probe. Prior to ablation,
the patients had a small tissue biopsy taken of the largest 1 or 2 ﬁ-
broid(s), using a 16-gauge Bard Magnum laparoscopic core biopsy nee-
dle (Bard Biopsy Systems, Tempe, AZ, USA). The tissue samples were
sent to the laboratory for routine pathologic analysis. The tip of the
handpiece was then placed in the same tract as the biopsy needle and
advanced to theﬁbroid, and the electrodeswere deployed if appropriate
based on the ﬁbroid size (Fig. 3). Fibroid ablation was then carried out
and the tract was coagulated during probe withdrawal to provide he-
mostasis (Fig. 4).
The 2 surgeons (S.Y.B. and B.K.) each perform more than 100 LM
procedures annually. Neither had prior experience with RFVTA.
As part of the pre-study training process, they attended the stan-
dard Acessa RFVTA course, which consists of didactic instruction, prac-
tice in a simulated laboratory environment, and proctoring of the
initial cases.
At the conclusion of surgery, the port sites were closed per standard
procedure. Standard post-procedure care included routine monitoring
of vital signs and monitoring for any signs of complications. Outcomes
data were collected on the appropriate case report forms for all partici-
pants. Any complications that occurred during and following the proce-
dure were documented.
The procedure timewas deﬁned as randomization time to closure
time for both groups. In addition, the total time in the operating
room, including the time of anesthesia induction, was documented,
as was the time in the post-anesthesia care unit/recovery room
(time from intake to discharge). The hospitalization time was de-
ﬁned as the time between induction of anesthesia and discharge
from the hospital.
Assessed for eligibility (n=110)
Excluded (n=54)
Analyzed (n=25)
Allocated to RFVTA (n=26)
Received allocated intervention (n=25)
Did not receive allocated intervention 
(procedure terminated because operating 
room emergency occurred that was not 
related to the participant) (n=1)
Allocated to LM (n=25)
Received allocated intervention (n=25)
Analyzed (n=25)
Randomized (n=51)
Intraoperative mapping (n=56)
Excluded (n=5)
1 patient had a large (>10 cm) 
fibroid and an IUD that was in place
2 patients had many fibroids and, if 
randomized to LM, would have had 
a hysterectomy
1 patient had no fibroids
1 patient had only 1 large (>10 cm) 
pedunculated fibroid
Fig. 1. Flow of patients through the study. Abbreviations: IUD, intrauterine device; LM, laparoscopic myomectomy; RFVTA, radiofrequency volumetric thermal ablation.
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regard to hospitalization timewas based on the following assumptions.
The null hypothesis was that RFVTA is more than 10% worse than
LM with regard to length of hospital stay, and the alternative hypoth-
esis was that this is not the case; this was tested using a 1-sided test
of noninferiority of RFVTA relative to LM with an α level of 0.025. The
mean ± SD length of hospital stay for patients undergoing myomecto-
my was assumed to be 15 ± 16 hours [11], so the null hypothesis
would be rejected if the length of stay for patients receiving RFVTA
was less than 16.5 hours (alternatively, if the length of stay for patients
receiving RFVTA subtracted from 16.5 hours was at least 0). The as-
sumed mean ± SD length of hospital stay for patients receiving RFVTA
was based on the results of a study conducted in the USA and assumed
to be 7 ± 4 hours (data not reported in the article [7]). Assuming that
the pooled SD of the difference in the length of hospital stay between
the 2 procedures is 11.7 hours, which is the square root of the mean
of the estimated variances of the 2 procedures, and that the difference
in the length of stay between procedures is 9.5 (16.5 – 7) hours, the
sample size required to reject the null hypothesis with a power of 0.80
was 50 (25 patients per group) (East version 5.4; Cytel, Cambridge,
MA, USA).
Analyses were performed using SAS version 9.2 (SAS Institute,
Cary, NC, USA). The signiﬁcance level associated with the P value
for the comparison between groups with regard to the length of hos-
pital stay was 0.025. Signiﬁcance levels of P values associated with
exploratory comparisons between groups presented in the paper
were set to 0.05.3. Results
Of 110 patients assessed for eligibility, 51 were randomized to the 2
interventions; the ﬁnal analysis included 25 patients in the RFVTA
group and 25 patients in the LM group (Fig. 1). Baseline demographics
and intraoperative uterine mapping characteristics for each group are
presented in Table 1. The predominant symptom reported by the pa-
tients in the RFVTA and LM groups was heavy menstrual bleeding
followed by urinary frequency, pelvic discomfort and pain, backache, lo-
calized pain, dysmenorrhea, urinary retention, increased abdominal
girth, dyspareunia, uterine pain, and sleep disturbance. There were no
signiﬁcant differences based on Fisher exact test between the 2 groups
with regard to any of these symptoms, although this could be because
of the relatively small number of patients in each group. Two patients
in each group reported infertility.
The mean time between the ﬁrst incision and closure of the port
sites was 1.1 ± 0.4 hours (median 1.1 hours, range 0.6–1.9 hours) for
the RFVTA group and 1.3 ± 0.6 hours (median 1.2 hours, range
0.4–2.9 hours) for the LM group (P = 0.16, t test). The mean time be-
tween arrival in post-anesthesia recovery and discharge from the hospi-
tal was 8.2 ± 5.3 hours (median 6.2 hours, range 2.5–22.7 hours) for
the RFVTA group and 28.0 ± 13.8 hours (median 20.6 hours, range
14.8–64.6 hours) for the LM group (P b 0.001, Wilcoxon test). The
mean hospitalization time was 10.0 ± 5.5 hours (median 7.8 hours,
range 4.2–25.5 hours [95% CI, 7.73–12.24]) for the RFVTA group and
29.9 ± 14.2 hours (median 22.6 hours, range 16.1–68.1 hours [95% CI:
24.09–35.79]) for the LMgroup. The P value for the test of noninferiority
Fig. 4. Intraoperative laparoscopic view of the serosal surface with good hemostasis
achieved post-ablation and second insertion of the radiofrequency handpiece tip for the
treatment of another ﬁbroid; the handpiece is to the left of the ultrasound probe.
Fig. 2. Ultrasound image taken during uterine mapping before randomization, showing a
5.25-cm intramural ﬁbroid.
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cant (P b 0.001, Wilcoxon test). The mean number of treated (RFVTA)
or excised (LM) ﬁbroids per patient was 2.8 ± 2.6 (median 2.0, rangeFig. 3. Ultrasound view of the radiofrequency needle array within the ﬁbroid capsule.1–9) and 2.0 ± 1.4 (median 1.0, range 1–6), respectively (P = 0.30,
Wilcoxon test). The total number of ﬁbroids treated by RFVTA and LM
was 71 and 49, respectively. The treated/excised ﬁbroids were catego-
rized by type for each treatment group (Table 2). The rate of treated/
excised ﬁbroids, expressed as a percentage of the ﬁbroids imaged by
LUS, was 98.6% (71/72) for RFVTA and 80.3% (49/61) for LM (Table 2).
For each RFVTA procedure, 2 trocars (1 for the ultrasound probe and
1 for the laparoscopic video) were used. In the LM procedures, 4–5 tro-
cars were used. The mean intraoperative blood loss was 16 ± 9 mL
(median 20 mL, range 0–30 mL) for the RFVTA procedures and 51 ±
57 mL (median 35 mL, range 10–300 mL) for the LM procedures
(P b 0.001, Wilcoxon test).
In the RFVTA group, 1 patient had an unplanned hospitalization be-
cause she developed vertigo; this was the only complication reported in
the RFVTA group. Four patients in the RFVTA group were hospitalized
as a standard-of-care measure because they underwent adhesiolysis in
addition to the ablative treatment. In the LM group, 1 patient had a
suprapubic port site hematoma, which was reported as a complication;
no other complicationswere reported in the LMgroup. All 25 patients in
the LMgroupwere hospitalized overnight tomonitor for potential post-
procedure bleeding, administer narcotic pain medications, and ascer-
tain their ability to walk by themselves and use the toilet.Table 1
Demographics and baseline (intraoperative) myoma characteristics.a,b
Variable RFVTA
(n = 25)
LM
(n = 25)
Age, y 40.0 ± 7.8 34.4 ± 6.1
Height, cm 166.0 ± 5.8 164.4 ± 5.9
Weight, kg 62.4 ± 8.9 64.9 ± 13.5
Race
White 25 (100.0) 25 (100.0)
Heavy menstrual bleeding 21 (84.0) 18 (72.0)
Total number of ﬁbroids 72 61
Number of ﬁbroids per patientc 2.9 ± 2.6 (2 [1–9]) 2.4 ± 1.6 (2 [1–6])
Fibroid type
Submucosal 0 (0.0) 2 (3.3)
Transmural 0 (0.0) 3 (4.9)
Intramural 33 (45.8) 26 (42.6)
IMAE 2 (2.8) 0 (0.0)
Subserosal 37 (51.4) 34 (55.7)
Pedunculated subserosal 0 (0.0) 2 (3.3)
Fibroid diameter, cmd 6.3 (2.6–18.8) 6.2 (1.9–15.2)
Diameter of largest myoma
treated, cm
8.7 9.2
Abbreviations: IMAE, intramural ﬁbroid abutting the endometrium; LM, laparoscopic
myomectomy; RFVTA, radiofrequency volumetric thermal ablation.
a Values are given as mean ± SD or number (percentage) unless indicated otherwise.
b Intraoperative myoma characteristics were evaluated by laparoscopic ultrasound
mapping of the uterus prior to treatment/excision.
c Values are given as mean ± SD (median [range]).
d Values are given as median (range).
Table 2
Types of treated and excised ﬁbroids.a,b
Variable RFVTA LM
Fibroid type
Submucosal 0 (0.0) 1 (2.0)
Transmural 0 (0.0) 1 (2.0)
Intramural 33 (46.5) 18 (36.7)
IMAE 2 (2.8) 0 (0.0)
Subserosal 36 (50.7) 33 (67.3)
Pedunculated subserosalb 0 (0.0) 2 (4.1)
Total number of ﬁbroids imaged on LUS 72 61
Total number of ﬁbroids treated/excised 71 49
Rate of ﬁbroids treated/excised, %c 98.6 80.3
Abbreviations: IMAE, intramural ﬁbroid abutting the endometrium; LM, laparoscopic
myomectomy; LUS, laparoscopic ultrasound; RFVTA, radiofrequency volumetric thermal
ablation.
a Values are given as number (percentage) unless indicated otherwise.
b Pedunculated subserosal ﬁbroids with thick stalks can be treated by RFVTA and are
not a contraindication. Pedunculated subserosal ﬁbroids with thin stalks are more easily
excised by myomectomy. Historically, RFVTA surgeons have excised these ﬁbroids. Be-
cause the present study was a randomized controlled trial of LM versus RFVTA, we did
not want to combine techniques/procedures in any patient.
c Expressed as a percentage of the number of ﬁbroids imaged on LUS.
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vessels occurred with either procedure, and there were no conversions
to laparotomy.
4. Discussion
Although the use and success of RFVTA of uterine ﬁbroids has been
reported in the literature [7–9,12], there have been no studies to date
comparing RFVTA with the current standard of care, LM. The present
study was a randomized clinical trial comparing the perioperative out-
comes of the 2 procedures—speciﬁcally, the number of trocars used, in-
traoperative blood loss, number of ﬁbroids treated, complications, and
times to discharge. These are important parameters to consider because
they indicate the comparative need for treatment resources and may
predict the quality of life after ﬁbroid treatment.
Several studies of operative time, intraoperative blood loss, and du-
ration of hospitalization associatedwith LMhave been reported. Bedient
et al. [13] retrospectively reviewed the charts of 41 women who had
undergone LM; the mean operating time was 1.93 ± 1.07 hours
(range 1.13–5.35 hours). Nezhat et al. [14] reported on LM surgical
times, intraoperative blood loss, and duration of postoperative hospital-
ization for 35 women undergoing LM. The mean surgical time was
3.38 hours (range 1.58–5.50 hours), the mean blood loss was 420 mL
(range 110–750 mL), and the mean duration of postoperative hospital-
ization was 1.05 days (range 1–3 days). The perioperative outcomes in
these 2 studies [13,14] may reﬂect standard-of-care results for LM.
The ﬁnding that the present surgeonswere able to access and ablate
more ﬁbroids by RFVTA than were excised at LM reﬂects the compre-
hensiveness of ﬁbroid RFVTA and the possibility to ablate small, intra-
mural myomas without a myometrial incision. The shorter operative
and hospitalization times and the lower intraoperative blood loss asso-
ciated with RFVTA indicate a lower burden overall to medical institu-
tions, patients, and society.
Surgeons are often concerned over the potential for intra- and post-
operative bleeding from myometrial incisions. In the present study,
there was a meaningful difference in intraoperative blood loss between
the 2 groups. Given the difference in the number of trocars used (2 for
RFVTA and 4–5 for LM) and the need for amorcellatorwith LM, patients
treated by LM were approximately twice as likely to experience bleed-
ing (hematoma) at a port site. In addition, the placement of trocars
carries an inherent risk of intra-abdominal injury [15].
Like all single-site studies, the present study has limitations. The
racial makeup of the participants was homogeneous (100% white); a
more heterogeneous population might have resulted in decreased bias.However, all participants had symptomatic ﬁbroids and their surgeons
had extensive experience in LM but no experience with RFVTA prior to
training for the study. Another limitation of the study as presented is
the lack of long-term data, including pregnancy outcomes. The partici-
pants will be followed for 5 years and pregnancy outcomes, symptom
improvement, and overall treatment satisfaction will be evaluated on
the basis of the participants’ responses to validated questionnaires.
In summary, RFVTA provided a safe and shorter operative and post-
operative experience for patients withmyomaswith less intraoperative
blood loss, treatment of a greater number of ﬁbroids, nomyometrial in-
cisions, and less fatigue compared with LM.
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